Oral Ketamine in the Palliative Care Setting: A Review of the Literature and Case Report of a Patient With Neurofibromatosis Type 1 and Glomus Tumor-Associated Complex Regional Pain Syndrome

American Journal of Hospice and Palliative Medicine

Volumn 29, Issue 4, 2012, Pages 308-317

  Soto, Eliezer ^a   Stewart, Douglas R ^b   Mannes, Andrew J ^a   Ruppert, Sarah L ^c   Baker, Karen ^a   Zlott, Daniel ^a   Handel, Daniel ^a   Berger, Ann M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

cancer pain; complex regional pain syndrome; neurofibromatosis type 1; neuropathic pain; oral ketamine; palliative care

Indexed keywords

EID: 84865463649     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909111416345     Document Type: Review

References (49)

1. Mercadante S,Arcuri E,Tirelli W,Cascuccio A.Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double blind, crossover, double-dose study.J Pain Symptom Manage. 2000;20 (4): 246-252.
2. Eichenberger U,Neff F,Sveticic G, et al.Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain and sensory thresholds.Anesth Analg. 2008;106 (4): 1265-1273.
3. Kiefer RT,Rohr P,Ploppa A, et al.Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study.Pain Med. 2008;9 (8): 1173-1201.
4. Rabben T,Skjelbred P,Oye I.Prolonged analgesic effect of ketamine, an N-Methyl-D aspartate receptor inhibitor, in patients with chronic pain.J Pharmacol Exp Ther. 1998;289 (2): 1060-1066.
5. Cull-Candy S,Brickley S,Farrant M.NMDA receptor subunits: diversity, development and disease.Curr Opin Neurobiol. 2001;11 (3): 327-335.
6. Dingledine R,Borges K,Bowie D,Traynelis SF.The glutamate receptor ion channels.Pharmacol Rev. 1999;51 (1): 7-62.
7. Paoletti P,Neyton J.NMDA receptor subunits: function and pharmacology.Curr Opin Pharmacol. 2007;7 (2): 39-47.
8. Lodge D,Johnson KM.Noncompetitive excitatory amino acid receptor antagonists.Trends Pharmacol Sci. 1990;11 (2): 81-86.
9. Rabben T,Oye I.Interindividual differences in the analgesic response to ketamine in chronic orofacial pain.Eur J Pain. 2001;5 (3): 233-240.
10. Chong C,Schug SA,Page-Sharp M,Jenkins B,Ilett KF.Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study.Clin Drug Invest. 2009;29 (5): 317-324.
11. Grant IS,Nimmo WS,Clements JA.Pharmacokinetics and analgesic effects of IM and oral ketamine.Br J Anaesth. 1981;53 (5): 805-810.
12. Yanagihara Y,Ohtani M,Kariya S, et al.Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers.Biopharm Drug Dispos. 2003;24 (1): 37-43.
13. Hagelberg NM,Peltoniemi MA,Saari TI, et al.Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine.Eur J Pain. 2010;14 (6): 625-629.
14. Blonk MI,Koder BG,Van Den Bemt PM,Huygen FJ.Use of oral ketamine in chronic pain management: a review.Eur J Pain. 2010;14 (5): 466-472.
15. Storr T,Quibell R.Can ketamine prescribed for pain cause damage to the urinary tract?.Palliat Med. 2009;23 (7): 670-672.
16. Grégoire MC,MacLellan DL,Finley GA.A pediatric case of ketamine-associated cystitis.Urology. 2008;71 (6): 1232-1233.
17. Mercadante S,Arcuri E,Ferrera P,Villari P,Mangione S.Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain.J Pain Symptom Manage. 2005;30 (5): 485-491.
18. Lauretti G,Lima I,Reis M,Prado W,Pereira N.Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.Anesthesiology. 1999;90 (6): 1528-1533.
19. Ishizuka P,Santos-Garcia JB,Kimito-Sakata R,Machado-Issy A,Mulich SL.Assessment of oral S(+) ketamine associated with morphine for the treatment of oncologic pain.Rev Bras Anestesiol. 2007;57 (1): 19-31.
20. Kotlińska-Lemieszek A.Subanesthetic ketamine: an essential adjuvant for intractable cancer pain.J Pain Symptom Manage. 2004;28 (2): 100-101.
21. Lloyd-Williams M.Ketamine for cancer pain.J Pain Symptom Manage. 2000;19 (2): 79-80.
22. Fitzgibbon EJ,Hall P,Schroder C,Seely J,Viola R.Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine.J Pain Symptom Manage. 2002;23 (2): 165-170.
23. Benitez-Rosario MA,Feria M,Salinas-Martin A,Martinez-Castillo LP,Martin-Ortega JJ.A retrospective comparison of the dose ratio between subcutaneous and oral ketamine.J Pain Symptom Manage. 2003;25 (5): 400-402.
24. Villanueva-Perez VL,Cerda-Olmedo G,Asensio-Samper JM, et al.Oral ketamine for the treatment of type I complex regional pain syndrome.Pain Pract. 2007;7 (1): 39-43.
25. Sakai T,Tomiyasu S,Ono T,Yamada H,Sumikawa K.Multiple sclerosis with severe pain and allodynia alleviated by oral ketamine.Clin J Pain. 2004;20 (5): 375-376.
26. Vick PG,Lamer TJ.Treatment of central post-stroke pain oral ketamine.Pain. 2001;92 (1-2): 311-313.
27. Nikolajsen L,Hansen PO,Jensen TS.Oral ketamine therapy in the treatment of postamputation stump pain.Acta Anaesthesiol Scand. 1997;41 (3): 427-429.
28. Furuhashi-Yonaha A,Iida H,Asano T, et al.Short- and long-term efficacy of oral ketamine in eight chronic pain patients.Can J Anaesth. 2002;49 (8): 886-887.
29. Kannan TR,Saxena A,Bhatnagar S,Barry A.Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients.J Pain Symptom Manage. 2002;23 (1): 60-65.
30. Kubota T,Miyata A.Successful use of ketamine for intractable burning pain of HTLV-1-associated myelopathy.J Pain Symptom Manage. 2005;30 (5): 397-399.
31. Okon T.Ketamine: an introduction for the pain and palliative medicine physician.Pain Physician. 2007;10 (3): 493-500.
32. Hoffmann V,Coppejans H,Vercauteren M,Adriaensen H.Successful treatment of postherpetic neuralgia with oral ketamine.Clin J Pain. 1994;10 (3): 240-242.
33. Haines DR,Gaines SP.N of 1 randomised controlled trials of oral ketamine in patients with chronic pain.Pain. 1999;83 (2): 283-287.
34. Enarson MC,Hays H,Woodroffe MA.Clinical experience with oral ketamine.J Pain Symptom Manage. 1999;17 (5): 384-386.
35. Gordon DB,Sehgal N,Schroeder ME,Cleary J.Treatment of pain crisis at end of life from severe lower extremity venous outflow obstruction with hyperalgesia and allodynia.J Pain. 2002;3 (3): 244-248.
36. Tobias JD,Phipps S,Smith B,Mulhern RK.Oral ketamine premedication to alleviate the distress of invasive procedures in pediatric oncology patients.Pediatrics. 1992;90 (4): 537-541.
37. Ozdemir D,Kayserili E,Arslanoglu S,Gulez P,Vergin C.Ketamine and midazolam for invasive procedures in children with malignancy: a comparison of routes of intravenous, oral, and rectal administration.J Trop Pediatr. 2004;50 (4): 224-228.
38. Gutstein HB,Johnson KL,Heard MB,Gregory GA.Oral ketamine preanesthetic medication in children.Anesthesiology. 1992;76 (1): 28-33.
39. Tammiga RY,Noordhoek M,Kroon J,Faber-Nijholt R.Ketamine anesthesia with or without diazepam premedication for bone marrow punctures in children with acute lymphoblastic leukemia.Pediatr Hematol Oncol. 2000;17 (5): 383-388.
40. Pellier I,Monrigal JP,Le Moine P, et al.Use of intravenous ketamine-midazolam association for pain procedures in children with cancer: a prospective study.Paediatr Anaesth. 1999;9 (1): 61-68.
41. Tsui BC,Davies D,Desai S,Malherbe S.Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma.J Pediatr Hematol Oncol. 2004;26 (10): 678-680.
42. Anghelescu DL.Ketamine use for radiation of opioid tolerance in a 5-year-old girl with end-stage abdominal neuroblastoma.J Pain Symptom Manage. 2005;30 (1): 1-3.
43. Conway M,White N,St. Jean C,Zempsky WT,Steven K.Use of continuous intravenous ketamine for end-stage cancer pain in children.J Pediatr Oncol Nurs. 2009;26 (2): 100-106.
44. Klepstad P,Borchgrevink P,Hval B,Fleet S,Kaasa S.Long term treatment with ketamine in a 12-year-old girl with severe neuropathic pain caused by a cervical spinal tumor.J Pediatr Hematol Oncol. 2001;23 (9): 616-619.
45. Fine PG.Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain.J Pain Symptom Manage. 1999;17 (4): 296-300.
46. Finkel JC,Pestieau SR,Quezado ZM.Ketamine as an adjuvant for treatment of cancer pain in children and adolescents.J Pain. 2007;8 (6): 515-521.
47. Ugur F,Gulcu N,Boyaci A.Oral ketamine for pain relief in a child with abdominal malignancy.Pain Med. 2009;10 (1): 120-121.
48. Brems H,Park C,Maertens O, et al.Glomus tumors in neurofibromatosis type 1: genetic, functional and clinical evidence of a novel association.Cancer Res. 2009;69 (18): 7393-7401.
49. Stewart DR,Sloan JL,Yao L, et al.Diagnosis, management, and complications of glomus tumors of the fingers in neurofibromatosis type 1.J Med Genet. 2010;47 (8): 525-532.